title: Promising early results for immunotherapy-antiangiogenesis combination.
authors.forename: Ken
authors.initials: K
authors.lastname: Garber
mesh_terms: D020533:Angiogenesis Inhibitors / Q000276:immunology* / Q000627:therapeutic use*; D000906:Antibodies / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000276:immunology; D000068258:Bevacizumab; D019496:Cancer Vaccines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007167:Immunotherapy / Q000379:methods; D000074324:Ipilimumab; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*
chemical_list: D020533:Angiogenesis Inhibitors; D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D019496:Cancer Vaccines; D007166:Immunosuppressive Agents; D000074324:Ipilimumab; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; C582435:pembrolizumab